EJNMMI Radiopharmacy and Chemistry
译名:欧洲核医学与分子影像学杂志-放射性药物与化学
3-5
2026
影响因子区间
—
平台估算
10%
2025
中国作者发文占比
17250 ZAR
收费
期刊简介:EJNMMI Radiopharmacy and Chemistry is a peer-reviewed journal focusing on the development of new imaging and radionuclide-based therapeutic agents for nuclear medicine and molecular imaging. Offers a platform for chemists, pharmacists, and basic scientists to present their work. Reports original research, review papers, guidelines, editorials, and letters to the editor. Specializes in novel radiochemistry, new radiopharmaceuticals, and molecular imaging agents. Addresses legislative issues related to the production and safety of imaging and radionuclide therapy agents. Shares a peer review database with other related journals for a comprehensive review process. Offers a platform for chemists, pharmacists, and basic scientists to present their work.; Reports original research, review papers, guidelines, editorials, and letters to the editor.; Specializes in novel radiochemistry, new radiopharmaceuticals, and molecular imaging agents.; Addresses legislative issues related to the production and safety of imaging and radionuclide therapy agents.; Shares a peer review database with other related journals for a comprehensive review process.
【译文】EJNMMI Radiopharmacy and Chemistry 是一本同行评审期刊,专注于开发用于核医学和分子成像的新型成像和基于放射性核素的治疗剂。为化学家、药剂师和基础科学家提供展示其工作的平台。报告原创研究、评论论文、指南、社论和给编辑的信。专门研究新型放射化学、新型放射性药物和分子成像剂。解决与成像和放射性核素治疗剂的生产和安全相关的立法问题。与其他相关期刊共享同行评审数据库,以进行全面的评审过程。为化学家、药剂师和基础科学家提供展示其工作的平台。报告原创研究、评论论文、指南、社论和给编辑的信件。专长于新型放射化学、新型放射性药物和分子成像剂。解决与成像和放射性核素治疗剂的生产和安全相关的立法问题。与其他相关期刊共享同行评审数据库,以进行全面的评审过程。

| 指标 | 当前值 | 近三年趋势 |
|---|---|---|
| JCR分区 | Q1 | 暂无 |
| 影响因子区间 | 3-5 | 暂无 |